West Pharmaceutical Services Inc. of Lionville said today it will lay off 250 employees - 13 percent of its tech-group workforce.

The move was prompted by Pfizer Inc.'s October decision to discontinue Exubera, an inhaled insulin product for which West made the inhalation device, West said in a statement.

The company expects to take a restructuring charge of $12 million to pay severance costs and to account for fixed asset write-downs. It said it will eventually see $7 million in annual operating savings.

The charge will amount to 5 cents per share this year, and 19 cents per share in 2008, the company estimated.

West also will take an impairment charge of between $11 million and $13.1 million in the fourth quarter as a result of the lost contract for the inhalation devices.

Shares were down 10 cents to $36.94 in noon trading on the New York Stock Exchange.

West makes components for injectable drug delivery, and products for the personal care, food and beverage markets.